Supreme Court dismisses suits against drug regulators, whistleblower says

Image
Reuters MUMBAI/NEW DELHI
Last Updated : Mar 11 2016 | 2:29 PM IST

By Zeba Siddiqui and Suchitra Mohanty

MUMBAI/NEW DELHI (Reuters) - The Supreme Court has refused to hear two lawsuits filed by one of the country's best-known whistleblowers which accused drugs and health regulators of failing to enforce safety standards, the whistleblower and his lawyer said on Friday.

Dinesh Thakur, who exposed dangerous practices in India's drugs industry in 2013, filed the public interest litigations in January, one of which alleges current drugs laws are "unconstitutional".

The suits sought a series of reforms, including harsher prosecution for manufacturers found to be selling substandard medicines or obtaining marketing approvals illegally.

Thakur, on his official Twitter account, said the Supreme Court refused to hear the cases on Friday and that he was "disappointed". He declined to comment on reasons for the refusal when contacted by Reuters, saying he had not yet received a court order.

Representatives at the Supreme Court, and the offices of the Central Drugs Standard Control Organisation and health ministry did not respond to requests for comment.

Thakur's lawyer and senior advocate at the Supreme Court, Raju Ramachandran, confirmed the court had refused to hear the cases. He declined to make any further comment.

"Unfortunately, the Supreme Court declined to admit either of the petitions but has given us liberty to approach any other appropriate forum for remedy," Thakur wrote on his blog. (http://dineshthakur.com/)

He declined to comment on possible options when contacted by Reuters.

(Reporting by Zeba Siddiqui in MUMBAI and Suchitra Mohanty in NEW DELHI; Editing by Miral Fahmy and Christopher Cushing)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 11 2016 | 2:09 PM IST

Next Story